A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
Latest Information Update: 30 Jun 2025
At a glance
- Drugs Brexanolone (Primary)
- Indications Postnatal depression
- Focus Registrational; Therapeutic Use
- Sponsors Lipocine
Most Recent Events
- 23 Jun 2025 According to a Lipocine media release, the data readout is expected in Q2-2026.
- 18 Jun 2025 Status changed from not yet recruiting to recruiting.
- 08 May 2025 According to a Lipocine media release, the Phase 3 study is expected to support a New Drug Application (NDA) submission in 2026.